ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk
Promis Neurosciences (NASDAQ:PMN) had its "buy" rating reaffirmed by analysts at HC Wainwright.
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference [Canadian Business Journal (Canada)]